Heather Anne Parsons, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
DNA, Neoplasm | 5 | 2017 | 1758 | 1.030 |
Why?
|
Breast Neoplasms | 20 | 2023 | 20817 | 0.990 |
Why?
|
Neoplasm, Residual | 3 | 2023 | 972 | 0.820 |
Why?
|
Estrogen Receptor alpha | 2 | 2020 | 577 | 0.640 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2021 | 933 | 0.500 |
Why?
|
Anticarcinogenic Agents | 1 | 2015 | 253 | 0.450 |
Why?
|
Receptor, erbB-2 | 6 | 2022 | 2416 | 0.410 |
Why?
|
Tamoxifen | 1 | 2015 | 981 | 0.370 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2024 | 9230 | 0.340 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 2015 | 949 | 0.300 |
Why?
|
Neoplasm Metastasis | 6 | 2021 | 4841 | 0.290 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 6 | 2024 | 11493 | 0.280 |
Why?
|
High-Throughput Nucleotide Sequencing | 6 | 2024 | 3598 | 0.270 |
Why?
|
Neoplasm Proteins | 1 | 2016 | 3703 | 0.230 |
Why?
|
Early Detection of Cancer | 1 | 2016 | 3086 | 0.200 |
Why?
|
Maintenance | 1 | 2021 | 25 | 0.200 |
Why?
|
Semen | 1 | 2023 | 316 | 0.190 |
Why?
|
Mutation | 12 | 2023 | 29784 | 0.160 |
Why?
|
Antineoplastic Agents | 1 | 2021 | 13668 | 0.160 |
Why?
|
Neoplasms | 7 | 2023 | 21672 | 0.160 |
Why?
|
Centrosome | 2 | 2015 | 201 | 0.150 |
Why?
|
Inflammatory Breast Neoplasms | 1 | 2019 | 143 | 0.150 |
Why?
|
Polymerase Chain Reaction | 3 | 2016 | 6172 | 0.150 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2022 | 3474 | 0.130 |
Why?
|
Neoadjuvant Therapy | 2 | 2024 | 2726 | 0.130 |
Why?
|
Prospective Studies | 6 | 2023 | 53280 | 0.130 |
Why?
|
Female | 24 | 2024 | 380197 | 0.120 |
Why?
|
Phlebotomy | 1 | 2015 | 141 | 0.120 |
Why?
|
Humans | 36 | 2024 | 744220 | 0.120 |
Why?
|
DNA Mutational Analysis | 3 | 2017 | 4188 | 0.120 |
Why?
|
Drug Therapy | 1 | 2016 | 497 | 0.110 |
Why?
|
DNA Copy Number Variations | 2 | 2021 | 1940 | 0.110 |
Why?
|
Loss of Heterozygosity | 1 | 2014 | 684 | 0.100 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2016 | 8426 | 0.100 |
Why?
|
Disease-Free Survival | 1 | 2021 | 6893 | 0.090 |
Why?
|
Premature Birth | 1 | 2022 | 1721 | 0.090 |
Why?
|
DNA Methylation | 1 | 2024 | 4289 | 0.090 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2017 | 1692 | 0.090 |
Why?
|
Mutation, Missense | 2 | 2015 | 2563 | 0.090 |
Why?
|
BRCA2 Protein | 1 | 2014 | 794 | 0.080 |
Why?
|
Prognosis | 3 | 2020 | 29050 | 0.080 |
Why?
|
Medical Oncology | 1 | 2020 | 2265 | 0.080 |
Why?
|
BRCA1 Protein | 1 | 2015 | 1149 | 0.080 |
Why?
|
DNA | 3 | 2023 | 7303 | 0.080 |
Why?
|
Survival Rate | 2 | 2020 | 12781 | 0.080 |
Why?
|
Combined Modality Therapy | 1 | 2020 | 8628 | 0.080 |
Why?
|
Sequence Analysis, DNA | 3 | 2024 | 4803 | 0.080 |
Why?
|
Adult | 9 | 2023 | 214035 | 0.070 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2014 | 1101 | 0.070 |
Why?
|
Bone Neoplasms | 1 | 2018 | 2525 | 0.070 |
Why?
|
Models, Genetic | 1 | 2015 | 3494 | 0.060 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2015 | 2916 | 0.060 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2015 | 2948 | 0.060 |
Why?
|
Biopsy | 1 | 2016 | 6757 | 0.060 |
Why?
|
Aged | 7 | 2023 | 163253 | 0.060 |
Why?
|
Sulfites | 1 | 2024 | 79 | 0.060 |
Why?
|
Cell Cycle Proteins | 1 | 2015 | 3461 | 0.060 |
Why?
|
Cell Movement | 1 | 2015 | 5216 | 0.060 |
Why?
|
Telomere-Binding Proteins | 1 | 2004 | 116 | 0.060 |
Why?
|
Middle Aged | 8 | 2021 | 213367 | 0.050 |
Why?
|
Quinolines | 2 | 2019 | 730 | 0.050 |
Why?
|
Retrospective Studies | 5 | 2023 | 77426 | 0.050 |
Why?
|
Neoplasm Staging | 3 | 2021 | 11007 | 0.050 |
Why?
|
Quality of Life | 1 | 2022 | 12805 | 0.050 |
Why?
|
Platinum | 1 | 2021 | 233 | 0.050 |
Why?
|
Predictive Value of Tests | 1 | 2016 | 15070 | 0.040 |
Why?
|
Liver Neoplasms | 1 | 2015 | 4252 | 0.040 |
Why?
|
Carboplatin | 1 | 2022 | 800 | 0.040 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2022 | 648 | 0.040 |
Why?
|
Nucleosomes | 1 | 2022 | 494 | 0.040 |
Why?
|
Taxoids | 1 | 2022 | 665 | 0.040 |
Why?
|
Heterozygote | 2 | 2015 | 2805 | 0.040 |
Why?
|
Breast | 2 | 2019 | 1969 | 0.040 |
Why?
|
Follow-Up Studies | 1 | 2020 | 39045 | 0.040 |
Why?
|
Epigenomics | 1 | 2023 | 903 | 0.040 |
Why?
|
Brain Neoplasms | 1 | 2019 | 8860 | 0.040 |
Why?
|
Nucleic Acid Denaturation | 1 | 2017 | 111 | 0.040 |
Why?
|
Chromosomes, Human, Pair 18 | 1 | 2018 | 245 | 0.040 |
Why?
|
Alleles | 2 | 2022 | 6938 | 0.040 |
Why?
|
Chromosomes, Human, Pair 19 | 1 | 2018 | 367 | 0.040 |
Why?
|
Cyclophosphamide | 1 | 2022 | 2236 | 0.040 |
Why?
|
Microchemistry | 1 | 2015 | 57 | 0.030 |
Why?
|
Cell Proliferation | 3 | 2015 | 10480 | 0.030 |
Why?
|
Colony-Forming Units Assay | 1 | 2015 | 354 | 0.030 |
Why?
|
Alkaline Phosphatase | 1 | 2018 | 865 | 0.030 |
Why?
|
Heredity | 1 | 2015 | 154 | 0.030 |
Why?
|
Paclitaxel | 1 | 2022 | 1707 | 0.030 |
Why?
|
Genotype | 2 | 2023 | 12956 | 0.030 |
Why?
|
Receptors, Estrogen | 1 | 2022 | 2186 | 0.030 |
Why?
|
Cell Line, Transformed | 1 | 2015 | 898 | 0.030 |
Why?
|
Hematopoiesis | 1 | 2023 | 2069 | 0.030 |
Why?
|
Blood Chemical Analysis | 1 | 2015 | 440 | 0.030 |
Why?
|
Hemolysis | 1 | 2015 | 420 | 0.030 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2022 | 3921 | 0.030 |
Why?
|
Radiation Tolerance | 1 | 2015 | 484 | 0.030 |
Why?
|
Gene Dosage | 1 | 2017 | 1251 | 0.030 |
Why?
|
Cancer Care Facilities | 1 | 2015 | 402 | 0.030 |
Why?
|
Hemoglobins | 1 | 2018 | 1533 | 0.030 |
Why?
|
Signal Transduction | 1 | 2015 | 23404 | 0.030 |
Why?
|
Immunoblotting | 1 | 2015 | 1682 | 0.030 |
Why?
|
Gene Targeting | 1 | 2015 | 880 | 0.030 |
Why?
|
Plasma | 1 | 2015 | 575 | 0.030 |
Why?
|
Aneuploidy | 1 | 2015 | 530 | 0.030 |
Why?
|
Tubulin | 1 | 2015 | 695 | 0.030 |
Why?
|
Genomic Instability | 1 | 2015 | 695 | 0.020 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2015 | 890 | 0.020 |
Why?
|
Chromosome Aberrations | 1 | 2018 | 1814 | 0.020 |
Why?
|
Homozygote | 1 | 2015 | 1786 | 0.020 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2018 | 1509 | 0.020 |
Why?
|
Cell Line, Tumor | 2 | 2017 | 16687 | 0.020 |
Why?
|
Antigens, Neoplasm | 1 | 2017 | 1987 | 0.020 |
Why?
|
Pilot Projects | 1 | 2022 | 8321 | 0.020 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2015 | 2649 | 0.020 |
Why?
|
Quinazolines | 1 | 2015 | 1356 | 0.020 |
Why?
|
Computational Biology | 1 | 2021 | 3523 | 0.020 |
Why?
|
Prostate-Specific Antigen | 1 | 2018 | 2478 | 0.020 |
Why?
|
Societies, Medical | 1 | 2020 | 3741 | 0.020 |
Why?
|
Gene Frequency | 1 | 2015 | 3588 | 0.020 |
Why?
|
Thiazoles | 1 | 2015 | 1484 | 0.020 |
Why?
|
Animals | 3 | 2016 | 168788 | 0.020 |
Why?
|
Phenotype | 2 | 2015 | 16365 | 0.020 |
Why?
|
Blotting, Western | 1 | 2015 | 5180 | 0.020 |
Why?
|
Signal Processing, Computer-Assisted | 1 | 2015 | 1537 | 0.020 |
Why?
|
Transfection | 1 | 2015 | 5892 | 0.020 |
Why?
|
Cell Cycle | 1 | 2015 | 2967 | 0.020 |
Why?
|
Genome | 1 | 2015 | 1808 | 0.020 |
Why?
|
RNA Interference | 1 | 2015 | 2890 | 0.020 |
Why?
|
Cell Line | 2 | 2015 | 15999 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2015 | 4201 | 0.020 |
Why?
|
Survival Analysis | 1 | 2018 | 10250 | 0.020 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2015 | 2938 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2015 | 5974 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2018 | 12244 | 0.020 |
Why?
|
Homeostasis | 1 | 2015 | 3339 | 0.020 |
Why?
|
Baculoviridae | 1 | 2004 | 118 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2020 | 7281 | 0.010 |
Why?
|
Software | 1 | 2017 | 4442 | 0.010 |
Why?
|
Age Factors | 1 | 2019 | 18367 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2022 | 25618 | 0.010 |
Why?
|
Glutathione Transferase | 1 | 2004 | 595 | 0.010 |
Why?
|
Oligonucleotides | 1 | 2004 | 572 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2015 | 14556 | 0.010 |
Why?
|
DNA, Complementary | 1 | 2004 | 2050 | 0.010 |
Why?
|
Protein Folding | 1 | 2004 | 843 | 0.010 |
Why?
|
Male | 3 | 2023 | 350027 | 0.010 |
Why?
|
Protein Structure, Tertiary | 1 | 2004 | 3846 | 0.010 |
Why?
|
Cohort Studies | 1 | 2019 | 40559 | 0.010 |
Why?
|
Kinetics | 1 | 2004 | 6474 | 0.010 |
Why?
|
Binding Sites | 1 | 2004 | 6116 | 0.010 |
Why?
|
Prostatic Neoplasms | 1 | 2017 | 11074 | 0.010 |
Why?
|
Risk Assessment | 1 | 2015 | 23337 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2015 | 17449 | 0.010 |
Why?
|
Time Factors | 1 | 2015 | 40063 | 0.010 |
Why?
|
United States | 1 | 2020 | 69867 | 0.010 |
Why?
|
Escherichia coli | 1 | 2004 | 4220 | 0.010 |
Why?
|
Protein Binding | 1 | 2004 | 9392 | 0.010 |
Why?
|
Risk Factors | 1 | 2015 | 72280 | 0.010 |
Why?
|
Mice | 1 | 2015 | 81178 | 0.000 |
Why?
|